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Objective
To evaluate whether poor nutrition is associated with
mortality in patients undergoing cytoreductive nephrectomy
(CN) for metastatic renal cell carcinoma (mRCC).
Patients and Methods
A multi-institutional review of prospective databases
identified 246 patients meeting inclusion criteria who
underwent CN for mRCC from 1993 to 2012. Nutritional
markers evaluated were: body mass index <18.5 kg/m2, serum
albumin <3.5 g/dL, or preoperative weight loss of ≥5%
of body weight. Primary outcomes were overall (OS) and
disease-specific survival (DSS). Secondary outcome was ‘early
mortality’ defined as death at ≤6 months of surgery. Survival
curves were estimated using the Kaplan–Meier product-limit
method and multivariate analysis using logistic regression was
used to test associations between nutritional markers and
survival outcomes.
Results
In all, 119 patients (median follow-up 17 months) were
categorised as having any abnormal nutrition parameter
(48%). Hypoalbuminaemia was the only independent
predictor of OS and DSS (OS: median 8 vs 23 months,
P < 0.001; DSS: 11 vs 33 months, P < 0.001). On multivariate
analysis, hypoalbuminaemia remained a significant predictor
of death for both overall [hazard ratio (HR) 2, 95% confidence
interval (CI) 1.4–2.8; P < 0.001) and disease-specific mortality
(HR 2.2, 95% CI 1.4–3.3; P < 0.001). Hypoalbuminaemia was
also associated with early mortality (overall: P < 0.001 and
disease specific: P = 0.002).
Conclusion
Patients with mRCC and hypoalbuminaemia undergoing CN
have decreased OS and CSS, and increased risk of all-cause
and disease-specific early mortality. As such, serum albumin
may help risk stratify patients selected as candidates for CN.
Furthermore, future work should evaluate whether nutritional
depletion is a modifiable risk factor.
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Introduction
Before 2001, the role of nephrectomy in the setting of mRCC
was largely undefined, and radical surgery was offered chiefly
for palliative purposes. However, two prospective randomised
trials showed that cytoreductive nephrectomy(CN) imparts a
survival advantage for patients with mRCC who then undergo
immunotherapy when compared with patients who receive
interferon-α alone [1–3]. Despite the advent of targeted
therapy and loss of enthusiasm for interferon-α [4–6], CN
continues to be a mainstay therapeutic option for patients
with mRCC [7].
CN may not benefit all patients and in fact may be harmful
to a subset of those who are destined to either have major
complications from surgery or to exhibit rapid disease
progression [8]. In fact, such patients may miss an opportunity
to receive potentially life-extending systemic targeted therapy
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[8–10]. Thus, preoperative risk stratification to identify
high-risk cohorts is extremely desirable but has proven to be
clinically challenging [11,12].
Poor nutritional status is a known predictor of survival in
various surgical settings [13–16]. Recently a robust association
between poor nutritional status and postoperative mortality in
patients with locoregional RCC was reported [17]. However,
identification of a relationship between nutritional status and
survival after CN is yet to be fully defined [18]. As such, the
purpose of the present study was to evaluate the association
between preoperative nutritional deficiency and poor survival
outcomes after CN.
Patients and Methods
After individual Institutional Review Board approval for the
creation and analysis of two prospectively maintained
databases (Fox Chase Cancer Center and Vanderbilt
University Medical Center), patients with mRCC treated with
CN from 1993 to 2012 were identified. Metastatic disease was
confirmed through biopsy or radiographic imaging and was
characterised as involving lung, bone, liver, brain, or other
sites. Patients with insufficient staging records, pathological
findings of a non-renal cell malignancy, history of previous
treatment for locoregional disease, and those without
appropriate nutritional status data were excluded from the
study. Surgery was performed via open, laparoscopic or
robotic approaches. Treating physicians determined
follow-up schedules based on their personal and institutional
clinical practice. Primary outcomes were overall (OS) and
disease-specific survival (DSS). Using data from both
the Southwestern Oncology Group 8949 and European
Organization for Research and Treatment of Cancer 30947
randomised trials first evaluating the use of CN in mRCC,
the OS advantage in the CN group was 6 months [2].
Therefore, a secondary outcome was ‘early mortality’ defined
as death at ≤6 months of surgery to evaluate if any net
benefit was obtained from CN. Follow-up was determined
from time of surgery to time of last contact with the patient
or date of death. Death dates were confirmed by death
certificate. Overall mortality vs disease-specific mortality was
determined by reconciliation of data from death certificates,
National Death Index, institutional tumour registries, and
physician documentation.
Although most of the data were collected prospectively,
medical records were reviewed retrospectively to obtain
missing and desired data points. Nutritional parameters
assessed included serum albumin, body mass index (BMI)
and percentage weight loss within the 6 months before
surgery with thresholds for abnormal parameters of: serum
albumin <3.5 g/dL, BMI <18.5 kg/m2, or unintentional
weight loss of ≥5% of total body weight. Consistent with
prior reports, survival outcomes were also evaluated between
patients using a composite classification for nutritional
deficiency [≥one parameter abnormal: serum albumin
<3.5 g/dL (hypoalbuminaemia), BMI <18.5 kg/m2, or
unintentional weight loss of ≥5% of total body weight]
compared with nutritionally replete patients (all parameters
normal) [17]. Each nutritional parameter was also evaluated
individually. Anaemia was defined as serum haematocrit
of <41% for men and <36% for women. Symptoms were
defined as local or metastatic if pain or discomfort at site
was attributable to RCC or systemic only if constitutional
symptoms were present. Preoperative renal function was
assessed with estimated GFR and chronic kidney disease
staged according to the National Kidney Foundation staging
system [19]. Pathological characteristics included tumour
stage, histological subtype, Fuhrman nuclear grade, presence
of sarcomatoid variant and nodal status. Pathological
classification of tumours was carried out in accordance with
the 2010 American Joint Committee on Cancer classification
system [20].
Association between nutritional status and patient and disease
characteristics was assessed using Fisher’s exact or chi-square
tests for categorical variables. Kaplan–Meier survival curves
were constructed from univariate analyses for DSS and OS
after CN, and significance was assessed using the log-rank test.
In multivariate survival analyses, Cox proportional hazards
models for OS and DSS were constructed adjusting for factors
significant and approaching significance on univariate
analysis. Statistical analysis was carried out using STATA
software (version 12.1).
Results
In all, 275 consecutive patients with mRCC treated with CN
from 1993 to 2012 were identified from two prospectively
maintained institutional databases. Of these 246 patients
met study inclusion criteria with a median (interquartile
range, IQR) age of 60 (52–67) years. The median (IQR)
follow-up was 17 (5–31) months. The patients’ demographic
characteristics are listed in Table 1. The majority of patients
were men (71.5%), had a preoperative Eastern Cooperative
Oncology Group Performance Status of 0–1 (90%), and
were treated with open radical nephrectomy (74%). Lung
metastases were present in 66% of patients with 17.5% of
patients having lung as the only site of metastasis. Bone
metastases were present in 36% of patients, while liver
and brain metastases were present in 17.9% and 5.3%,
respectively. In all, 57% of patients had multiple sites of
metastatic involvement.
Summarised in Table 2, of our total cohort, hypoalbuminaemia
was present in 25% (62/246) while nearly half (48.4%) met at
least one criteria for nutritional deficiency. Predictors of OS
and DSS on univariate analysis are summarised in Tables 3
and 4. In an initial multivariable model, patients meeting the
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Table 1 Patient demographics.
Variable Total,N (%) Low serum albumin,N (%) Normal serum albumin,N (%) P
All patients 246 (100.0) 62 (25.2) 184 (74.8)
Men 176 (71.5) 44 (71.0) 132 (71.7) 1
Age at CN, years:
≤50 51 (20.7) 17 (27.4) 34 (18.5)
51–60 73 (29.7) 16 (25.8) 57 (31.0)
61–70 84 (34.1) 20 (32.3) 64 (34.8)
71–80 33 (13.4) 7 (11.3) 26 (14.1)
>80 5 (2.0) 2 (3.2) 3 (1.6) 0.504
Race:
Black 17 (6.9) 5 (8.1) 12 (6.5)
Other 229 (93.1) 57 (91.9) 172 (93.5) 0.772
Year of CN:
1993–1995 3 (1.2) 0 3 (1.6)
1996–2000 13 (5.3) 6 (9.7) 7 (3.8)
2001–2005 101 (41.1) 31 (50.0) 70 (38.0)
2006–2010 113 (45.9) 23 (37.1) 90 (48.9)
2011–2012 16 (6.5) 2 (3.2) 14 (7.6) 0.093
ECOG PS:
0–1 216 (87.8) 51 (82.3) 165 (89.7)
>1 24 (9.8) 9 (14.5) 15 (8.2)
NS 6 (2.4) 2 (3.2) 4 (2.2) 0.21
CCI:
<7 123 (50.0) 35 (56.5) 88 (47.8)
7–9 106 (43.1) 21 (33.9) 85 (46.2)
>9 17 (6.9) 6 (9.7) 11 (6.0) 0.185
Symptoms:
None 23 (9.3) 3 (4.8) 20 (10.9)
Local only 63 (25.6) 17 (27.4) 46 (25.0)
Metastatic only 65 (26.4) 5 (8.1) 60 (32.6)
Systemic only 34 (13.8) 15 (24.2) 19 (10.3)
>1 61 (24.8) 22 (35.5) 39 (21.2) <0.001
Renal insufficiency:
Yes 61 (24.8) 16 (25.8) 45 (24.5) 0.866
Anaemia:
Yes 155 (63.0) 55 (88.7) 100 (54.3) <0.001
Nephrectomy:
Open 182 (74.0) 46 (74.2) 136 (73.9)
Laparoscopic 63 (25.6) 16 (25.8) 47 (25.5)
Robotic 1 (0.4) 1 (1.6) 0 1
Intraoperative transfusion:
Yes 90 (36.6) 36 (58.1) 54 (29.3) <0.001
Site of metastasis:
Lung 163 (66.3) 52 (83.9) 111 (60.3) 0.001
Bone 89 (36.2) 15 (24.2) 74 (40.2) 0.032
Liver 44 (17.9) 17 (27.4) 27 (14.7) 0.034
Brain 13 (5.3) 4 (6.5) 9 (4.9) 0.74
NOS 123 (50.0) 31 (50.0) 92 (50.0) 0.99
No. metastatic sites at CN:
1 105 (42.7) 23 (37.1) 82 (44.6)
2 100 (40.7) 23 (37.1) 77 (41.8)
3 38 (15.4) 14 (22.6) 24 (13.0)
>3 3 (1.2) 2 (3.2) 1 (0.5) 0.09
Pathological tumour stage:
<pT3b 174 (70.7) 36 (58.1) 138 (75.0) 0.036
pT3b 32 (13.0) 11 (17.7) 21 (11.4)
>pT3b 40 (16.3) 15 (24.2) 25 (13.6)
Pathological nodal stage:
N0/NX 173 (70.3) 41 (66.1) 132 (71.7)
N+ 73 (29.7) 21 (33.9) 52 (28.3) 0.424
Fuhrman grade:
I–II 40 (16.3) 3 (4.8) 37 (20.1)
III–IV 200 (81.3) 57 (91.9) 143 (77.7)
NS 6 (2.4) 2 (3.2) 4 (2.2) 0.009
Histology:
Clear cell 199 (80.9) 50 (80.6) 149 (81.0)
Non-clear cell 47 (19.1) 12 (19.4) 35 (19.0)
Papillary 16 (6.5) 1 (1.6) 15 (8.2)
Mixed 9 (3.7) 2 (3.2) 7 (3.8)
Unclassified 8 (3.3) 4 (6.5) 4 (2.2)
Collecting duct 8 (3.3) 1 (1.6) 7 (3.8)
Sarcomatoid 5 (2.0) 3 (4.8) 2 (1.1)
Medullary 1 (0.4) 1 (1.6) 0 0.002
Sarcomatoid component:
Yes 59 (24.0) 22 (35.5) 37 (20.1) 0.017
CCI, Charlson comorbidity index; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NOS, not otherwise specified.
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criteria for nutritional deficiency using the composite score
were at higher risk of overall [hazard ratio (HR) 1.70, 95% CI
1.18–2.45; P = 0.004] and disease-specific (HR 1.81, 95% CI
1.20–2.73; P = 0.005) mortality. A second multivariate analysis
using the individual nutritional deficiency parameters
separately (Tables 3 and 4), controlling for factors significant
and approaching significance on univariate analysis, only
hypoalbuminaemia, polymetastases, non-clear cell histology,
and high grade remained predictors of all-cause mortality
(Table 3), while unintentional weight loss of ≥5% of total body
weight was not significant. Only one patient had a BMI of
<18.5 kg/m2, precluding evaluation in our multivariate model.
Additionally, only serum albumin level, polymetastases,
non-clear cell histology and stage >T3b were predictive
of disease-specific mortality on multivariate analysis
(Table 4).
Evaluating serum albumin levels independently, all-cause and
disease-specific mortality was observed in 91.9% and 74.2% of
patients with hypoalbuminaemia vs 69.6% and 51.1% in
patients with normal levels, respectively. Kaplan–Meier
survival analysis revealed significant differences in median OS
(8 vs 23 months; P < 0.001; Fig. 1) and DSS (11 vs 33 months;
P < 0.001; Fig. 2) in patients with low and normal serum
albumin. Survival outcomes were analysed at 6 months to
evaluate rates of early postoperative mortality. In multivariate
analyses, adjusting for age, tumour grade, Charleston
comorbidity index, presence of polymetastases, clear cell and
sarcomatoid histologies, hypoalbuminaemia was significantly
associated with all-cause (HR 1.91, 95% CI 1.31–2.78; P <
0.001) and disease-specific (HR 2.07, 95% CI 1.35–3.18; P <
0.001) mortality. At 6 months, both all-cause [56.5% (95% CI
43.3–67.7%) vs 80.6% (95% CI 74.1–85.7 %); P < 0.001] and
disease-specific [62.6% (95% CI 48.9–73.6%) vs 84.3% (95% CI
Table 2 Patient distribution of nutritional status.
Parameter (N = 246) No. patients (%)
Serum albumin, g/dL:
<3.5 62 (25)
>3.5 153 (62)
BMI, kg/m2:
<18.5 1 (0.4)
>18.5 224 (91)
Weight loss, %:
≥5 85 (35)
<5 160 (65)
Composite nutrition status:
Nutritionally deficient 119 (48)
Nutritionally replete 127 (52)
Number of abnormal parameters:
1 90 (76)
2 29 (24)
3 0
Table 3 Cox univariate and multivariate regression analysis of OS.
Univariable Multivariable
HR 95% CI P HR 95% CI P
Low serum albumin 2.35 1.71–3.23 <0.001 1.91 1.31–2.78 <0.001
Weight loss >5% 1.48 1.10–2.00 0.01 1.30 0.92–1.84 0.142
Age 1.00 0.99–1.01 0.971 1.01 1.00–1.02 0.203
CCI >10 2.15 0.79–5.80 0.132 1.32 0.43–4.02 0.631
ECOG PS >1 1.19 0.89–1.60 0.233 1.22 0.89–1.67 0.215
Anaemia 1.51 1.11–2.05 0.009 1.02 0.71–1.46 0.906
Intraoperative
transfusion
1.70 1.27–2.28 <0.001 1.24 0.86–1.80 0.255
Symptoms:
none Referent
local only 1.65 0.91–2.99 0.099 1.39 0.75–2.58 0.298
systemic only 2.39 1.26–4.52 0.007 1.33 0.67–2.64 0.419
metastatic only 1.21 0.66–2.20 0.539 1.34 0.71–2.52 0.364
>1 1.74 0.96–3.17 0.07 1.18 0.62–2.25 0.621
Metastatic sites:
0–1 Referent
>1 1.95 1.44–2.64 <0.001 2.19 1.59–3.03 <0.001
Pathology:
<T3b ref
T3b 1.49 0.99–2.25 0.058 1.11 0.70–1.77 0.658
>T3b 2.25 1.55–3.25 <0.001 1.29 0.83–2.00 0.259
clear cell 0.60 0.42–0.85 0.004 0.53 0.34–0.82 0.004
high grade 2.16 1.44–3.25 <0.001 1.72 1.11–2.66 0.015
sarcomatoid
component
1.80 0.67–4.87 0.247 0.59 0.18–1.93 0.38
node positive 1.36 1.00–1.85 0.051 0.86 0.60–1.23 0.406
CCI, Charlson comorbidity index; ECOG PS, Eastern Cooperative Oncology Group
Performance Status.
Table 4 Cox univariate and multivariate regression analysis of DSS.
Univariable Multivariable
HR 95% CI P HR 95% CI P
Low serum albumin 2.57 1.79–3.69 <0.001 2.07 1.35–3.18 0.001
Weight loss >5% 1.75 1.25–2.45 0.001 1.32 0.90–1.95 0.158
Age 1.00 0.98–1.01 0.856 1.01 0.99–1.02 0.262
CCI >10 2.08 0.66–6.55 0.211 1.51 0.40–5.63 0.543
ECOG PS >1 1.37 0.98–1.93 0.064 1.27 0.88–1.82 0.195
Anaemia 1.60 1.12–2.29 0.01 1.21 0.73–1.67 0.651
Intraoperative
transfusion
1.94 1.39–2.71 <0.001 1.21 0.79–1.84 0.376
Symptoms:
none Referent
local only 2.56 1.14–5.73 0.022 1.77 0.77–4.07 1.181
systemic only 3.50 1.49–8.21 0.004 1.59 0.64–3.94 0.313
metastatic only 2.05 0.91–4.59 0.082 2.04 0.88–4.74 0.096
>1 2.61 1.16–5.88 0.021 1.85 0.78–4.37 0.162
Metastatic sites:
0–1 Referent
>1 1.86 1.31–2.62 <0.001 1.95 1.35–2.83 <0.001
Pathology:
<T3b Referent
T3b 1.59 0.99–2.54 0.053 1.57 0.93–2.67 0.093
>T3b 2.49 1.64–3.77 <0.001 1.68 1.03–2.75 0.038
clear cell 0.63 0.42–0.95 0.027 0.53 0.32–0.88 0.015
high grade 2.04 1.29–3.24 0.002 1.58 0.96–2.62 0.072
sarcomatoid
component
1.72 0.54–5.41 0.357 0.53 0.13–2.21 0.387
node positive 1.42 1.00–2.02 0.051 0.87 0.58–1.32 0.519
CCI, Charlson comorbidity index; ECOG PS, Eastern Cooperative Oncology Group
Performance Status.
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78.1–88.9%); P = 0.002) survival differed significantly for
patients with hypoalbuminaemia compared with patients with
normal albumin.
Discussion
In this large multi-institutional cohort of patients with mRCC,
low preoperative serum albumin was an independent
predictor of both overall and disease-specific mortality after
CN. Indeed, patients with hypoalbuminaemia had a >50%
reduction in OS and DSS when compared with patients with
normal serum albumin levels and were at double the risk for
early mortality.
These findings are highly significant, as the role of CN in the
era of effective targeted therapy is yet to be fully defined [7].
Benefits of CN have only been shown in patients who
uniformly received systemic therapy in the form of
interferon-α after surgery, and clinical trials are underway to
establish the survival role and timing of CN in the targeted
therapy era [21,22]. In fact, >30% of patients fail to receive
systemic therapy after CN in contemporary cohorts [8,10], as a
large proportion of these patients do not receive systemic
therapy due to rapid disease progression, perioperative
morbidity and/or death [8,10]. Clearly, these patients are
ill-served by cytoreductive surgery and unnecessarily incur
surgical morbidity at the end of life, while foregoing an
opportunity to receive potentially efficacious targeted therapy.
As such, appropriate risk stratification of patients who present
with metastatic disease is highly desirable to optimise the
decision between CN or a trial of targeted therapy before
surgery [7].
Progress in quantifying risk before CN recently has been
reported [9,18]. Examining a cohort of patients undergoing
CN, Culp et al. [9], incorporated seven preoperative variables
into a risk-group based model to identify those who benefit
most from CN. These and other predictors were then
combined into pre- and post-operative multivariable models
to predict DSS at 6 and 12 months after CN [18]. They then
constructed a nomogram (area under the curve = 0.76) to
assess 6-month probability of death after cytoreductive
surgery [18].While the multivariable predictive models
described may help identify patients with mRCC likely to
benefit from CN, our present study identifies serum albumin
as the single most important predictor of OS and DSS in
patients undergoing CN. Using a single clinical parameter
rather than obtaining results from a nomogram may
provide an advantage to practitioners for quick clinical
application.
Serum albumin level represents an easily quantifiable
and a potentially modifiable preoperative risk factor that
has been extensively evaluated across various surgical
disciplines, encompassing both benign and malignant disease
states. In fact, robust data support the association between
nutritional status, improved outcomes and decreased
treatment costs [23–25]. Until recently, nutritional status
has received only limited attention within urological
oncology. One of the first studies examining nutritional
status in patients with genitourinary malignancy evaluated
patients undergoing radical cystectomy for localised
bladder cancer [26]. Patients were classified as nutritionally
deplete based on preoperative serum albumin levels, BMI
or degree of perioperative weight loss and incurred worse
perioperative (90-day) and overall mortality as compared
with nutritionally replete patients. Similarly, these
parameters were examined in patients with locoregional
(non-metastatic) RCC with nutritionally deficient patients
Fig. 1 Kaplan–Meier analysis for OS in patients with low and normal
serum albumin levels.
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Fig. 2 Kaplan–Meier analysis for DSS in patients with low and normal
serum albumin levels.
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exhibiting higher 3-year overall and cancer-specific
mortality [17].
Definitions of nutritional depletion vary [27]. Although
nutritional deficiency metrics, such as the Nutritional Risk
Screening tool (NRS), which assess nutritional status using
weight loss, BMI, food intake, and disease severity, have a
role in prospective studies, proponents of these metrics
readily admit that quantification of food intake and
disease severity are often qualitative and arbitrary.
Furthermore, these metrics are impractical for retrospective
assessments [27].
Recently, in urological literature, quantification of nutritional
deficiency using serum albumin, BMI and weight loss has
gained significant traction [17,18,26]. In fact this metric is
generally readily quantifiable in routine clinical practice and
was a strong predictor of poor outcomes in our cohort.
However, our present data indicate that in patients with
mRCC, serum albumin alone, independent of BMI or weight
loss, was the component of the nutritional deficiency status
associated with poor outcomes.
Previous reports show that serum albumin was abnormal
in only 5% of patients with non-metastatic kidney cancer
[17] and 6% of those with localised bladder cancer [26].
In our present cohort 25% had abnormal serum albumin
levels preoperatively. As such, our present data show that
patients with mRCC who underwent surgical intervention
had a five-fold increased risk of being malnourished
than patients with localised urological malignancies
[17,26,27].
Our present data are consistent with previous reports
showing that patients who have hypoalbuminaemia exhibit
worse clinical outcomes than patients with normal albumin
levels [9]. In fact patients with low serum albumin who
underwent CN were at a 1.4-fold higher risk of 6-month
all-cause and disease-specific mortality. These trends
continued as the cohorts were followed long term, as patients
with low albumin were 90% more likely to succumb to RCC
and 80% more likely to meet an overall mortality end point
at 17 months of median follow-up. In fact, patients with
hypoalbuminaemia had a marked reduction in median OS
(11 vs 26 months; P < 0.001) and DSS (17 vs 46 months;
P < 0.001) when compared with counterparts with normal
levels.
Across various cancers, modulation of core factors, such as
systemic inflammation and surgical stress, may be mediated
via nutritional status, thus influencing the host’s immune
response. As such, nutritional repletion may harbour potential
to enhance efficacy of existing therapies or improve survival
outright [28,29]. The present data do not elucidate whether
hypoalbuminaemia represents a marker of poor outcome or a
modifiable factor that can be targeted to improve survival in
patients with metastatic disease. However, these data do
underscore the importance of nutritional status in patient
outcomes. Furthermore, our present report should serve as a
catalyst for further work to better understand if correction of
nutritional status affords a therapeutic opportunity for patients
with mRCC.
Similar to other retrospective studies, the present study has
limitations. As with all retrospective data, treatment choice
was not randomised resulting in the likelihood of selection
bias. Specifically, despite controlling for all available clinically
relevant and statistically significant covariates, unmeasured
confounders as well as parameters not significant on
univariate analysis may influence our present results.
Indeed, controlling for clinical and pathological factors
indicative of tumour stage in the multivariable analysis,
hypoalbuminaemia was independently associated with worse
outcomes. Nevertheless, patients with hypoalbuminaemia had
more advanced disease, which may confound our present
findings. Unfortunately, in this dataset where a large number
of patients probably travelled a long distance for surgery,
data about receipt of systemic therapy and readmission
rates were not fully captured limiting our ability to evaluate
these factors. Nevertheless, relative strengths include the
multi-institutional design, harnessing two prospectively
managed databases that are vigorously maintained with
robust processes to update vital status. In the absence of
rigorously tested consensus criteria to define poor nutritional
status in patients before renal surgery, the parameters used
in the present study were available in all patients, objective,
and easily obtainable from preoperative data and nutritional
status variables.
In conclusion, our present data underscore the role of
hypoalbuminaemia as an independent risk factor for overall
and disease-specific mortality in patients with mRCC
undergoing CN. Serum albumin (a readily available, easily
measured parameter) when low, identifies patients at
increased risk for early mortality and is highly prevalent in
patients with advanced RCC.We believe these data and
recent data from other institutions would spark interest in
determining whether poor nutrition is a modifiable risk or
simply a marker of poor prognosis. Certainly, if a trial of
targeted therapy is chosen upfront or if surgical intervention
is delayed for any reason, dietary intervention to potentially
correct hypoalbuminaemia is not likely to harm and may
offer benefits.
Source of Funding
This publication was supported by the National Cancer
Institute at the National Institutes of Health (grant number:
P30 CA006927, RU) and the Department of Defense,
Physician Research Training Award (A.K.). No financial
disclosures.
356
© 2014 The Authors
BJU International © 2014 BJU International
Corcoran et al.
Conflict of Interests
No authors have any conflict of interests related to this
manuscript to report.
References
1 Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus
interferon-alfa-based immunotherapy compared with interferon alfa
alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;
358: 966–70
2 Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H,
Crawford ED. Cytoreductive nephrectomy in patients with metastatic
renal cancer: a combined analysis. J Urol 2004; 171: 1071–6
3 Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed
by interferon Alfa-2b compared with interferon Alfa-2b alone for
metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655–9
4 Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated
results for sunitinib compared with interferon alfa in patients with
metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584–90
5 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa,
or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:
2271–81
6 Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med 2007; 356: 125–34
7 Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of
targeted therapy for renal cell carcinoma. Curr Urol Rep 2012; 13:
38–46
8 Kutikov A, Uzzo RG, Caraway A et al. Use of systemic therapy and
factors affecting survival for patients undergoing cytoreductive
nephrectomy. BJU Int 2010; 106: 218–23
9 Culp SH, Tannir NM, Abel EJ et al. Can we better select patients with
metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer
2010; 116: 3378–88
10 O’Malley RL, Brewer KA, Hayn MH et al. Impact of cytoreductive
nephrectomy on eligibility for systemic treatment and effects on survival:
are surgical complications or disease related factors responsible? Urology
2011; 78: 595–600
11 Trinh QD, Bianchi M, Hansen J et al. In-hospital mortality and failure to
rescue after cytoreductive nephrectomy. Eur Urol 2013; 63: 1107–14
12 Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive
nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson
Cancer Center experience. Urology 2007; 69: 835–8
13 Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by
surgery compared with surgery alone for localized esophageal cancer.
N Engl J Med 1998; 339: 1979–84
14 Garth AK, Newsome CM, Simmance N, Crowe TC. Nutritional status,
nutrition practices and post-operative complications in patients with
gastrointestinal cancer. J Hum Nutr Diet 2010; 23: 393–401
15 Alves A, Panis Y, Mathieu P et al. Postoperative mortality and morbidity
in French patients undergoing colorectal surgery: results of a prospective
multicenter study. Arch Surg 2005; 140: 278–84
16 Mullen JT, Davenport DL, Hutter MM et al. Impact of body mass index
on perioperative outcomes in patients undergoing major intra-abdominal
cancer surgery. Ann Surg Oncol 2008; 15: 2164–72
17 Morgan TM, Tang D, Stratton KL et al. Preoperative nutritional status is
an important predictor of survival in patients undergoing surgery for
renal cell carcinoma. Eur Urol 2011; 59: 923–8
18 Margulis V, Shariat SF, Rapoport Y et al. Development of accurate
models for individualized prediction of survival after cytoreductive
nephrectomy for metastatic renal cell carcinoma. Eur Urol 2013; 63:
947–52
19 National Kidney Foundation, Inc. NKF KDOQI Guidelines, 2002. 2002.
Available at: http://www2.kidney.org/professionals/KDOQI/guidelines
_ckd/p4_class_g1.htm. Accessed November 2014
20 Edge SB, Joint A. Committee on Cancer. AJCC Cancer Staging Manual,
7th edn. New York: Springer, 2010
21 Bex A, Jonasch E, Kirkali Z et al. Integrating surgery with targeted
therapies for renal cell carcinoma: current evidence and ongoing trials.
Eur Urol 2010; 58: 819–28
22 ClinicalTrials.gov. Clinical Trial to Assess the Importance of Nephrectomy
(CARMENA). 2009. Available at: http://clinicaltrials.gov/show/
NCT00930033. Accessed October 2014
23 Gustafsson UO, Ljungqvist O. Perioperative nutritional management in
digestive tract surgery. Curr Opin Clin Nutr Metab Care 2011; 14:
504–9
24 Fearon KC, Jenkins JT, Carli F, Lassen K. Patient optimization for
gastrointestinal cancer surgery. Br J Surg 2013; 100: 15–27
25 Huhmann MB, August DA. Perioperative nutrition support in cancer
patients. Nutr Clin Pract 2012; 27: 586–92
26 Gregg JR, Cookson MS, Phillips S et al. Effect of preoperative nutritional
deficiency on mortality after radical cystectomy for bladder cancer. J Urol
2011; 185: 90–6
27 Karl A, Rittler P, Buchner A et al. Prospective assessment of
malnutrition in urologic patients. Urology 2009; 73: 1072–6
28 Heys SD, Walker LG, Deehan DJ, Eremin OE. Serum albumin: a
prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb
1998; 43: 163–8
29 Veenhof AA, Vlug MS, van der Pas MH et al. Surgical stress response
and postoperative immune function after laparoscopy or open surgery
with fast track or standard perioperative care: a randomized trial. Ann
Surg 2012; 255: 216–21
Correspondence: Alexander Kutikov, MD, Division of
Urologic Oncology, Fox Chase Cancer Center-Temple
University Health System, 333 Cottman Avenue, Philadelphia,
PA 19111, USA.
e-mail: alexander.kutikov@fccc.edu
Abbreviations: BMI, body mass index; CN, cytoreductive
nephrectomy; DSS, disease-specific survival; HR, hazard ratio;
IQR, interquartile range; OS, overall survival; mRCC,
metastatic RCC.
© 2014 The Authors
BJU International © 2014 BJU International 357
Hypoalbuminaemia is associated with mortality in patients undergoing CN
